Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
BIVI 
Biovie Inc (BIVI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/17/2025: BIVI (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $12
1 Year Target Price $12
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -91.38% | Avg. Invested days 15 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 14.40M USD | Price to earnings Ratio - | 1Y Target Price 12 |
Price to earnings Ratio - | 1Y Target Price 12 | ||
Volume (30-day avg) 1 | Beta 0.71 | 52 Weeks Range 1.42 - 75.00 | Updated Date 10/18/2025 |
52 Weeks Range 1.42 - 75.00 | Updated Date 10/18/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -12.12 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -48.28% | Return on Equity (TTM) -101.64% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -2124493 | Price to Sales(TTM) - |
Enterprise Value -2124493 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -11.66 | Shares Outstanding 7537480 | Shares Floating 7494520 |
Shares Outstanding 7537480 | Shares Floating 7494520 | ||
Percent Insiders 3.36 | Percent Institutions 1.48 |
Upturn AI SWOT
Biovie Inc
Company Overview
History and Background
BioVie Inc., formerly known as NanoViricides, Inc., was founded in 2005. Initially focused on antiviral therapies, it shifted its focus to developing therapies for neurodegenerative and metabolic diseases. A significant milestone was the acquisition of certain assets related to NE3107 from Nervive in 2017, marking its pivot towards Alzheimer's disease and cancer.
Core Business Areas
- Neurodegenerative Diseases: Development of NE3107 for Alzheimer's disease and other neurodegenerative disorders.
- Cancer: Development of NE3107 as a potential treatment for cancer, focusing on its anti-inflammatory properties.
- Metabolic Diseases: Exploration of NE3107's potential in treating metabolic diseases, such as NASH.
Leadership and Structure
The leadership team includes Cuong V. Do, Ph.D. (Chief Executive Officer), and various other executives overseeing clinical development, finance, and operations. The company structure is typical of a clinical-stage biotech, with departments focused on research and development, clinical trials, and regulatory affairs.
Top Products and Market Share
Key Offerings
- NE3107: NE3107 is BioVie's lead drug candidate, currently in Phase 3 clinical trials for Alzheimer's disease and being investigated for cancer and metabolic diseases. Market share data is not applicable at this stage as it is still in development. Competitors in Alzheimer's include Eisai/Biogen (LEQEMBI) and Eli Lilly (donanemab). In cancer, competitors are diverse and depend on the specific cancer type targeted.
Market Dynamics
Industry Overview
The biotechnology industry is highly competitive and characterized by rapid technological advancements and stringent regulatory requirements. The Alzheimer's disease market is significant due to the growing aging population and lack of effective treatments. The cancer therapy market is also substantial, with continuous innovation and demand for new therapies.
Positioning
BioVie is a clinical-stage biotechnology company focused on developing NE3107, aiming to address unmet needs in Alzheimer's, cancer, and metabolic diseases. Its competitive advantage lies in the unique mechanism of action of NE3107 as an anti-inflammatory agent targeting specific pathways involved in these diseases.
Total Addressable Market (TAM)
The Alzheimer's disease market is projected to reach hundreds of billions of dollars. The cancer therapy market is also similarly large. BioVie is positioning itself to capture a portion of these markets if NE3107 proves effective and receives regulatory approval.
Upturn SWOT Analysis
Strengths
- Novel Mechanism of Action of NE3107
- Potential for Broad Application Across Multiple Diseases
- Strong Intellectual Property Protection
Weaknesses
- Clinical-Stage Company with No Approved Products
- High Cash Burn Rate
- Dependence on Successful Clinical Trial Outcomes
Opportunities
- Positive Clinical Trial Results
- Partnerships with Larger Pharmaceutical Companies
- Expansion into New Therapeutic Areas
Threats
- Clinical Trial Failures
- Regulatory Hurdles
- Competition from Established Pharmaceutical Companies
Competitors and Market Share
Key Competitors
- LLY
- BIIB
- JNJ
Competitive Landscape
BioVie faces significant competition from established pharmaceutical companies with approved Alzheimer's therapies and extensive resources. Its competitive advantage lies in the novel mechanism of action of NE3107 and its potential to address unmet needs.
Growth Trajectory and Initiatives
Historical Growth: BioVie's historical growth is characterized by the evolution of its drug development pipeline and financing activities.
Future Projections: Future growth is dependent on the successful completion of clinical trials for NE3107 and potential partnerships or acquisitions.
Recent Initiatives: Recent initiatives include advancing NE3107 into Phase 3 clinical trials for Alzheimer's disease and exploring its potential in cancer and metabolic diseases.
Summary
BioVie is a clinical-stage biotech company focused on NE3107. The company's strength lies in the unique mechanism of action of their lead candidate. However, they face risks typical of clinical-stage companies, including dependence on clinical trial success and a high cash burn rate. Success of NE3107 clinical trials will determine their success, and should be watched closely, as well as cash burn rate and funding.
Peer Comparison
Sources and Disclaimers
Data Sources:
- BioVie Inc. SEC Filings
- Company Website
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor. Market share data is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Biovie Inc
Exchange NASDAQ | Headquaters Carson City, NV, United States | ||
IPO Launch date 2014-05-05 | President, CEO & Director Mr. Cuong Viet Do M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 13 | Website https://bioviepharma.com |
Full time employees 13 | Website https://bioviepharma.com | ||
BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States. The company develops BIV201, that is in phase 2 for the treatment of ascites due to chronic liver cirrhosis. It also develops NE3107 that is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease; and in Phase 2 clinical trial to treat Parkinson's disease, as well as for the long COVID program. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.